natgillin/translations-raw huggingface dataset:
The mean terminal half-life of somatropin after intravenous administration in growth hormone deficient adults is about 0.4 hours. 
Pri odraslih s pomanjkanjem rastnega hormona je po intravenski uporabi somatropina srednja končna razpolovna doba okoli 0,4 ure.
Long-term treatment of children with growth disturbance due to chronic renal insufficiency System Organ 
Dolgotrajno zdravljenje otrok z motnjami v rasti zaradi kronične ledvične insuficience
Carbohydrate metabolism 
Presnavljanje ogljikovih hidratov
The top of the vial and of the cartridge should be wiped with an antiseptic solution in order to prevent contamination of the contents. 
Zgornji del viale in vložka obrišite z antiseptično raztopino, da preprečite kontaminacijo vsebine.
Leukaemia has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin. 
• levkemija (O njej so poročali pri majhnem številu bolnikov s pomanjkanjem rastnega hormona, pri čemer so bili nekateri zdravljeni s somatropinom.
Push up the plunger slowly back to the correct dose. 
Bat počasi potiskajte navzgor, dokler ne odmerite pravega odmerka zdravila.
However, after subcutaneous administration of Omnitrope powder and solvent for solution for injection, a half-life of 3 hours is achieved. 
Po subkutani uporabi zdravila Omnitrope prašek in vehikel za raztopino za injiciranje traja razpolovna doba 3 ure.
Higher doses may be necessary if the rate of growth is too low. 
Če je stopnja rasti prepočasna, bodo morda potrebni večji odmerki.
Somatropin treatment should be stopped at kidney transplantation. 
Ob presaditvi ledvic je treba zdravljenje s somatropinom prekiniti.
Prader-Willi syndrome, for improvement of growth and body composition in paediatric patients Generally a dose of 0.035 mg/kg body weight per day or 1.0 mg/m2 body surface area per day is recommended. 
Prader-Willijev sindrom (PWS), za izboljšanje rasti in sestave telesa pri pediatričnih bolnikih Običajen priporočen odmerek je 0,035 mg/kg telesne mase na dan ali 1,0 mg/m telesne površine na dan.
- Turn the vial with the solvent upside down and withdraw all the solvent from the vial. 
- Vialo z vehiklom obrnite navzdol in iz nje izčrpajte ves vehikel.
- Take the vial with the powder and push the needle through the rubber membrane of the vial. 
- Vzemite vialo s praškom in potisnite iglo skozi gumijasto membrano.
Use only with Omnitrope Pen 5. 
Uporabljajte samo z injekcijskim peresnikom Omnitrope Pen 5.
The incidence of these adverse reactions is related to the administered dose, the age of patients, and possibly inversely related to the age of patients at the onset of growth hormone deficiency. 
Pogostnost pojava teh neželenih reakcij je odvisna od odmerka zdravila, bolnikove starosti in morda v obratnem sorazmerju z njegovo starostjo ob pojavu pomanjkanja rastnega hormona.
Long-term treatment of children with growth disturbance due to insufficient secretion of growth hormone 
Dolgotrajno zdravljenje otrok z motnjami v rasti zaradi nezadostnega izločanja rastnega hormona
• Store in the original package in order to protect from light. 
• Shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
Patients and caregivers have to receive appropriate training and instruction on the proper use of the Omnitrope vials, the cartridges with solvent, the transfer set and the pen from the physician or other suitable qualified health professionals. 
Zdravniki ali drugo ustrezno usposobljeno osebje morajo bolnike in negovalno osebje ustrezno poučiti o pravilni uporabi vial, vložkov s z vehiklom, seta za prenos in peresnika Omnitrope.
- Adult onset: Patients who have severe growth hormone deficiency associated with multiple hormone deficiencies as a result of known hypothalamic or pituitary pathology, and who have at least one known deficiency of a pituitary hormone not being prolactin. 
Odrasli - Nadomestno zdravljenje odraslih z izrazitim pomanjkanjem rastnega hormona - Začetek v odrasli dobi: bolniki, ki imajo hudo pomanjkanje rastnega hormona, povezano s pomanjkanjem številnih hormonov kot posledica znane bolezni hipotalamusa ali hipofize ter ki imajo pomanjkanje najmanj enega hipofiznega hormona, vendar ne prolaktina; diagnozo pomanjkanja rastnega hormona se pri teh bolnikih potrdi ali ovrže z ustreznim dinamičnim testom.
Use only with SurePal 5. 
Uporabljajte samo z injekcijskim peresnikom SurePal 5.
In children • Stiffness in the arms and legs 
Pri otrocih • togost rok in nog
Your doctor will show you how to inject Omnitrope. 
Zdravnik ali sestra vam bo pokazal, kako si injicirati zdravilo Omnitrope.
- Use the transfer set for transferring all the solvent from the cartridge into the vial. 
- Vzemite set za prenos, da boste prenesli ves vehikel iz vložka v vialo.
Use the transfer set for transferring the solvent from the cartridge into the vial. 
Uporabite set za prenos vehikla iz vložka v vialo.
Do not use Omnitrope 
Ne uporabljajte zdravila Omnitrope
- Leave the cartridge in the pen, put the cap on the pen, and store it in the refrigerator. 
- Vložek pustite v injekcijskem peresniku, ga zaprite z zaporko in shranite v hladilniku.
Children with Prader-Willi syndrome 
Otroci s Prader-Willijevim sindromom
Pack sizes of 1 and 5. 
Velikost pakiranja po 1 in 5.
The following instructions explain how to inject Omnitrope 1.3 mg/ml yourself. 
Navodila v nadaljevanju pojasnjujejo, kako si lahko sami injicirate zdravilo Omnitrope, 1,3 mg/ml.
1.5 ml of solution in a cartridge (colourless type I glass) with plunger and a blue ring (for Omnitrope 15 mg/1.5 ml solution for injection only) on one side (siliconised bromobutyl), a disc (bromobutyl) and a cap (aluminium) on the other side. 
1,5 ml raztopine v vložku (brezbarvno steklo tipa I) z batom in modrim obročkom (samo za zdravilo Omnitrope 15 mg/1,5 ml raztopine za injiciranje) na eni strani (silikonizirani bromobutil), ploščico (bromobutil) ter zaporko (aluminij) na drugi strani.
Use a sterile, disposable syringe (e.g. 2 ml syringe) and needle (e.g. 0.33 mm x 12.7 mm) to withdraw all the solvent from the vial. 
Uporabite sterilno injekcijsko brizgo za enkratno uporabo (npr. 2-mililitrsko injekcijsko brizgo) in iglo (npr. 0,33 mm x 12,7 mm), da odstranite ves vehikel iz stekleničke.
Inject the solution by pushing the plunger all the way down gently. 
Raztopino injicirajte tako, da počasi potiskate bat navzdol do konca.
Injecting Omnitrope - Put the cartridge with the dissolved Omnitrope into the pen for injection. 
Injiciranje zdravila Omnitrope - Vložek z raztopljenim zdravilom Omnitrope vstavite v peresnik za injiciranje.
STATEMENT OF ACTIVE SUBSTANCE Somatropin 6.7 mg (20 IU)/ml. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN 6,7 mg somatropina (20 i.e.)/ml.
1.5 ml of solution in a cartridge (colourless type I glass) with plunger on one side (siliconised bromobutyl), a disc (bromobutyl) and a cap (aluminium) on the other side. 
1,5 ml raztopine v vložku (brezbarvno steklo tipa I) z batom na eni strani (silikonizirani bromobutil), ploščico (bromobutil) ter zaporko (aluminij) na drugi strani.
Rarely, an inflammation of the pancreas has been reported in patients treated with growth hormone. 
Redko so pri bolnikih, zdravljenih z rastnim hormonom, poročali o vnetju trebušne slinavke.
The active substance of Omnitrope is somatropin. 
Zdravilna učinkovina v zdravilu Omnitrope je somatropin.
and injection needle (e.g. 0.25 mm x 8 mm) for subcutaneous injection (not supplied in the pack). 
(npr. 1-mililitrsko) in injekcijsko iglo (npr. 0,25 mm x 8 mm) za subkutano injiciranje (ki je ni v ovojnini) - 2 blazinici iz vate za čiščenje (ki ju ni v ovojnini).
- Take the vial with solvent and the sterile, disposable syringe (e.g. 2 ml syringe) and needle (e.g. 0.33 mm x 12.7 mm). 
- Vzemite vialo z vehiklom in sterilno injekcijsko brizgo za enkratno uporabo (npr. 2-mililitrsko) ter iglo (npr. 0,33 mm x 12,7 mm).
The following instructions explain how to inject Omnitrope 5 mg/ml yourself. 
Navodila v nadaljevanju pojasnjujejo, kako si lahko sami injicirate zdravilo Omnitrope, 5 mg/ml.
NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Solvent for Omnitrope (water for injections) Subcutaneous use. 
Vehikel za zdravilo Omnitrope (voda za injekcije) subkutana uporaba
All patients with PWS should be evaluated for sleep apnoea and monitored if sleep apnoea is suspected.Patients should be monitored for signs of respiratory infections, which should be diagnosed as early as possible and treated aggressively. 
Pri vseh bolnikih je treba biti pozoren na morebitne znake okužbe dihal, jih čim prej diagnosticirati in agresivno zdraviti.
The solution is for single use only. 
Raztopina je le za enkratno uporabo.
Patients and caregivers have to receive appropriate training and instruction on the proper use of the Omnitrope cartridges and the pen from the physician or other suitable qualified health professionals. 
Zdravniki ali drugo ustrezno usposobljeno osebje morajo bolnike in negovalno osebje ustrezno poučiti o pravilni uporabi vložkov in injekcijskega peresnika Omnitrope.
How to use Omnitrope 
Kako uporabljati zdravilo Omnitrope
Testing for antibodies to somatropin should be carried out in any patient with otherwise unexplained lack of response. 
Sposobnost vezave teh protiteles je majhna in učinka na stopnjo rasti ni. Testiranje za protitelesa za somatropin je treba opraviti pri vseh bolnikih, pri katerih pomanjkanja odziva ni mogoče pojasniti na drugačen način.
The manufacturer's instructions with each pen must be followed for loading the cartridge, attaching the injection needle and for the administration. 
Izdelovalčeva navodila, ki so priložena injekcijskemu peresniku, je treba upoštevati pri polnjenju vložka, pritrditvi injekcijske igle in pri uporabi.
Very common side effects (likely to occur in more than 1 in 10 patients) include: In adults 
Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov) vključujejo: Pri odraslih
Omnitrope 5 mg/ml is supplied in a vial containing the active substance as a powder and the solvent filled in a cartridge. 
Omnitrope 5 mg/ml je v viali, ki vsebuje zdravilno učinkovino v obliki praška in vehikel v vložku.
- After reconstitution, Omnitrope is given as an injection under the skin. 
- Po pripravi se zdravilo Omnitrope injicira pod kožo.
However, after subcutaneous administration of Omnitrope 5 mg/1.5 ml, Omnitrope 10 mg/1.5 ml solution for injection, a half-life of 3 hours is achieved. 
Po subkutani uporabi zdravila Omnitrope 5 mg/1,5 ml, Omnitrope 10 mg/1,5 ml raztopina za injiciranje traja razpolovna doba 3 ure.
Although rare, pancreatitis should be considered in somatropin-treated children who develop abdominal pain. 
Primeri so sicer redki, vendar pa je pri otroku, ki se zdravi s somatropinom, v primeru pojava bolečine v trebuhu treba pomisliti na pankreatitis.
An increased chromosome fragility has been observed in one in vitro study on lymphocytes taken from patients after long term treatment with somatropin and following the addition of the radiomimetic drug bleomycin. 
V preskušanju in vitro na limfocitih, ki so jih odvzeli bolnikom, ki so se dolgo časa zdravili s somatropinom in poleg tega jemali radiomimetično zdravilo bleomicin, se je zvečala krhkost kromosomov.
- Be sure that the tip of the syringe is in the Omnitrope reconstituted solution. 
- Prepričajte se, da je konica injekcijske brizge v pripravljeni raztopini zdravila Omnitrope.
This will keep the Omnitrope solution sterile and prevent leaking. 
Tako bo raztopina Omnitrope ostala sterilna in ne bo odtekala.
• Numbness/tingling 
• otopelost/ščemenje
Assemble the pen following the instructions for use. 
Peresnik sestavite tako, kot piše v navodilih za uporabo.
In adults Omnitrope is used to 
Zdravilo Omnitrope se uporablja pri odraslih za
However, after subcutaneous administration of Omnitrope 15 mg/1.5 ml solution for injection, a half life of 2.76 hours is achieved. 
Po subkutani uporabi zdravila Omnitrope 15 mg/1,5 ml raztopina za injiciranje traja razpolovna doba 2,76 ure.
Other ingredients: 
Pomožne snovi:
The glass cartridge is irreversibly integrated in a transparent container and assembled to a plastic mechanism with a threaded rod at one extremity. 
Stekleni vložek je neločljivo vgrajen v prozoren vsebnik; na eni strani ima nameščen plastičen mehanizem z nazobčanim potisnikom.
Powder in a vial (type I glass) with a stopper (fluor-resin laminated butyl rubber), a strip (aluminium) and a cap (green polypropylene flip-off), and 1 ml of solvent in a cartridge (type I glass) with a stopper (fluor-resin laminated chlorobutyl elastomer), a strip (lacquered aluminium) and a cap (white polypropylene flip-off). 
Prašek v viali (steklo tipa I) z zamaškom (butilkavčuk, laminiran s fluorovo smolo), trak (aluminij) in zaporko (zelena odtržna zaporka iz polipropilena) in 1 ml vehikla v vložku (steklo tipa I) z zamaškom (klorobutilelastomer, laminiran s fluorovo smolo), trakom (lakirani aluminij) ter zaporko (bela odtržna zaporka iz polipropilena).
Growth disturbance due to insufficient secretion of growth hormone in paediatric patients Generally a dose of 0.025 - 0.035 mg/kg body weight per day or 0.7 - 1.0 mg/m2 body surface area per day is recommended. 
Motnje rasti zaradi nezadostnega izločanja rastnega hormona pri pediatričnih bolnikih Običajen priporočen odmerek je 0,025 do 0,035 mg/kg telesne mase na dan ali 0,7 do 1,0 mg/m telesne površine na dan.
The solvent is clear and colourless. 
Raztopina je bistra in brezbarvna.
- The contents must be clear and colourless. 
- Vsebina mora biti bistra in brezbarvna.
- Insert the cartridge into the pen for injection. 
- Vložek vstavite v peresnik za injiciranje.
Clean the injection site with an alcohol swab and administer Omnitrope by subcutaneous injection. 
Mesto injiciranja očistite z blazinico iz vate, namočeno v alkohol, in injicirajte zdravilo Omnitrope subkutano.
Push the needle fitted to the syringe through the rubber membrane. 
Iglo na injekcijski brizgi potisnite skozi gumijasto membrano.
Powder in a vial (type I glass) with a stopper (fluor-resin laminated butyl rubber), a strip (aluminium) and a cap (violet polypropylene flip-off), and 1 ml of solvent in a vial (type I glass) with a stopper (fluor-resin laminated chlorobutyl elastomer), a strip (lacquered aluminium) and a cap (white polypropylene flip-off). 
Prašek v viali (steklo tipa I) z zamaškom (butilkavčuk, laminiran s fluorovo smolo), trakom (aluminij) in zaporko (vijoličasta odtržna zaporka iz polipropilena) in 1 ml vehikla v viali (steklo tipa I) z zamaškom (klorobutilelastomer, laminiran s fluorovo smolo), trakom (lakirani aluminij) ter zaporko (bela odtržna zaporka iz polipropilena).
Injecting Omnitrope 
Injiciranje zdravila Omnitrope
For patients with diabetes mellitus, the insulin dose may require adjustment after somatropin therapy is instituted. 
Pri bolnikih s sladkorno boleznijo bo morda treba po začetku zdravljenja s somatropinom prilagoditi odmerek insulina.
Clinical trials in adults with GHD 
Klinična preskušanja pri odraslih s PRH
Rare side effects (likely to occur in fewer than 1 in 1,000 patients) include: In children 
Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov) vključujejo: Pri otrocih
Children with Turner syndrome: 0.045-0.050 mg/kg body weight per day or 1.4 mg/m2 body surface area per day. 
Otroci s Turnerjevim sindromom: 0,045-0,050 mg/kg telesne mase na dan ali 1,4 mg/m telesne površine na dan.
Omnitrope 1.3 mg/ml is supplied in a vial containing the active substance as a powder and the solvent filled in a vial for single use. 
Omnitrope 1,3 mg/ml je v viali za enkratno uporabo, ki vsebuje zdravilno učinkovino v obliki praška in vehikel.
Store in the original pen in order to protect from light. 
Shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
In general these adverse reactions are mild to moderate, arise within the first months of treatment and subside spontaneously or with dose-reduction. 
Ponavadi so reakcije blage do zmerne, pojavijo se v prvih mesecih zdravljenja, izginejo pa sami od sebe ali po zmanjšanju odmerka.
The content must be clear and colourless. 
Vsebina mora biti bistra in brezbarvna.
Omnitrope 10 mg/1.5 ml solution for injection 18 months. 
Omnitrope 10 mg/1,5 ml raztopina za injiciranje 18 mesecev.
How to inject Omnitrope 1.3 mg/ml 
Kako si je treba injicirati zdravilo Omnitrope 1,3 mg/ml
Omnitrope 15 mg/1.5 ml solution for injection 18 months. 
Omnitrope 15 mg/1,5 ml raztopina za injiciranje 18 mesecev.
Growth disturbance in chronic renal insufficiency A dose of 0.045 - 0.050 mg/kg body weight per day (1.4 mg/m2 body surface area per day) is recommended. 
Motnje rasti pri kronični ledvični insuficienci Priporočen odmerek je 0,045 do 0,05 mg/kg telesne mase na dan (1,4 mg/m telesne površine na dan).
Treatment should not be used in children who have almost stopped growing after puberty. 
Otroci po puberteti, ki so skoraj nehali rasti, naj se ne zdravijo s tem zdravilom.
- Eliminate any air bubbles. 
- Odstranite zračne mehurčke.
• Store and transport refrigerated (2°C-8°C). 
• Zdravilo shranjujte in prevažajte na hladnem (2 °C-8 °C).
Eliminate air bubbles if necessary. 
Odstranite morebitne zračne mehurčke.
Each ml of solution contains 10 mg of somatropin (corresponding to 30 IU). 
En mililiter raztopine vsebuje 10 mg somatropina (kar ustreza 30 i.e.).
How to inject Omnitrope 5 mg/ml 
Kako si je treba injicirati zdravilo Omnitrope, 5 mg/ml
- The solution should be clear after removal from the refrigerator. 
- Po hranjenju raztopine v hladilniku mora biti ta bistra.
Children with chronic renal (kidney) insufficiency 
Otroci s kronično renalno (ledvično) odpovedjo
Bring the syringe to the correct dose needed. 
Preverite, da bo v injekcijski brizgi tolikšen odmerek, kot ga potrebujete.
Cases of leukaemia (rare or very rare) have been reported in growth hormone deficient children treated with somatropin and included in the post-marketing experience. 
Pri otrocih s pomanjkanjem rastnega hormona, zdravljenih s somatropinom in vključenih v izkušnje v obdobju trženja, so poročali o primerih levkemije (redkih ali zelo redkih).
Transfer the solution back into the cartridge using the transfer set. 
- Za prenos raztopine nazaj v vložek uporabite set za prenos.
Each ml of solution contains 3.3 mg of somatropin (corresponding to 10 IU) One cartridge contains 5.0 mg (corresponding to 15 IU) of somatropin in 1.5 ml. 
En mililiter raztopine vsebuje 3,3 mg somatropina (ustreza 10 i.e.) En vložek vsebuje 5,0 mg (ustreza 15 i.e.) somatropina v 1,5 ml.
Omnitrope 5 mg/1.5 ml solution for injection 2 years. 
Omnitrope 5 mg/1,5 ml raztopina za injiciranje 2 leti.
STATEMENT OF ACTIVE SUBSTANCE Somatropin 10 mg (30 IU)/ml. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN 10 mg somatropina (30 i.e.)/ml.
STATEMENT OF ACTIVE SUBSTANCE Somatropin 3.3 mg (10 IU)/ml. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN 3,3 mg somatropina (10 i.e.)/ml.
Therefore caution should be exercised when Omnitrope is administered to breast-feeding women. 
Zato je pri doječih materah, ki prejemajo zdravilo Omnitrope, potrebna previdnost.
Omnitrope 5 mg/1.5 ml solution for injection Omnitrope 10 mg/1.5 ml solution for injection Omnitrope 15 mg/1.5 ml solution for injection 
Omnitrope 5 mg/1,5 ml raztopina za injiciranje Omnitrope 10 mg/1,5 ml raztopina za injiciranje Omnitrope 15 mg/1,5 ml raztopina za injiciranje
Uncommo n ≥ 1/1,000 to < 1/100 
Organski sistem zelo pogosti pogosti ≥ 1/100 do občasni do < 1/100
Blood cortisol decreased‡ 
Preiskave znižanje kortizola v krvi‡
How to inject Omnitrope 
Kako si je treba injicirati zdravilo Omnitrope
After reconstitution, one vial contains 1.3 mg somatropin (corresponding to 4 IU) per ml. 
Po rekonstituciji ena viala vsebuje 1,3 mg somatropina (ustreza 4 i.e.) na ml.
Use only with SurePal 15. 
Uporabljajte samo z injekcijskim peresnikom SurePal 15.
Always use this medicine exactly as your doctor or pharmacist or nurse has told you. 
Pri uporabi tega zdravila natančno upoštevajte navodila zdravnika, farmacevta ali medicinske sestre.
The treatment should be discontinued at renal transplantation. 
Po presaditvi ledvic je treba zdravljenje prekiniti.
After reconstitution, one cartridge contains 5 mg somatropin (corresponding to 15 IU) per ml. 
Po rekonstituciji en vložek vsebuje 5 mg somatropina (ustreza 15 i.e.) na ml.
• During treatment with somatropin, tell your doctor if you show signs of upper airway obstruction (including starting to snore or worsening of snoring), your doctor will need to examine you and may interrupt treatment with somatropin. 
• Povejte svojemu zdravniku, če imate med zdravljenjem s somatropinom znake zapore zgornjih dihalnih poti (vključno s tem, da ste začeli smrčati ali smrčite močneje).
Administer the appropriate dose by subcutaneous injection using a sterile pen needle. 
Odmerek injicirajte subkutano s sterilno iglo peresnika.
A subcutaneous dose of 5 mg of Omnitrope powder and solvent for solution for injection in healthy adults results in plasma Cmax values of 71 ± 24 µg/l (mean ± SD) and median tmax value of 4 hours (range 2-8 hours), respectively. 
Po subkutani uporabi 5 mg zdravila Omnitrope prašek in vehikel za raztopino za injiciranje pri zdravih odraslih je Cmax 71 ± 24 μg/l (srednja vrednost ± SD) in mediana tmax 4 ure (razpon 2 - 8 ur).
Growth disturbance in short children/adolescents born small for gestational age (SGA) A dose of 0.035 mg/kg body weight per day (1 mg/m2 body surface area per day) is usually recommended until final height is reached (see section 5.1). 
Običajen priporočen odmerek je 0,035 mg/kg telesne mase na dan (1 mg/m telesne površine na dan), dokler se ne doseže končne višine (glejte poglavje 5.1).
Powder: glycine, disodium hydrogen phosphate heptahydrate, sodium dihydrogen phosphate dihydrate Solvent: benzyl alcohol, water for injections 
Prašek: glicin, natrijev hidrogenfosfat heptahidrat, natrijev dihidrogenfosfat dihidrat Vehikel: benzilalkohol, voda za injekcije
After reconstitution and the first use the cartridge should remain in the pen and has to be kept in a refrigerator (2°C - 8°C) for a maximum of 21 days. 
Po rekonstituciji in prvi uporabi mora vložek ostati v peresniku in shranjen v hladilniku (2 °C - 8 °C) največ 21 dni.
One cartridge contains 15 mg (corresponding to 45 IU) of somatropin in 1.5 ml. 
En vložek vsebuje 15 mg (ustreza 45 i.e.) somatropina v 1,5 ml.
Collect necessary items before you begin: - a cartridge with Omnitrope solution for injection. 
Preden začnete, si pripravite vse potrebno: - vložek z raztopino za injiciranje zdravila Omnitrope.
Arthralgia* Myalgia* Musculoskeletal stiffness* 
mialgija* mišišnoskeletna okorelost*
What Omnitrope contains 
Kaj vsebuje zdravilo Omnitrope
Omnitrope 10 mg/1.5 ml solution for injection Each ml of solution contains 6.7 mg of somatropin* (corresponding to 20 IU) One cartridge contains 1.5 ml corresponding to 10 mg somatropin* (30 IU). 
Omnitrope 10 mg/1,5 ml raztopina za injiciranje En mililiter raztopine vsebuje 6,7 mg somatropina* (ustreza 20 i.e.).
Clean the site of injection with an alcohol swab. 
Mesto injiciranja očistite z blazinico iz vate, namočeno v alkohol.
It may cause toxic reactions and anaphylactoid reactions in infants and children up to 3 years old. 
Pri otrocih, starih do 3 let, lahko povzroči toksične in anafilaktoidne reakcije.
Ask for advice from your doctor before you stop using Omnitrope. 
Preden prenehate uporabljati zdravilo Omnitrope, prosite zdravnika za nasvet.
Use only with SurePal 10. 
Uporabljajte samo z injekcijskim peresnikom SurePal 10.
Omnitrope 10 mg/1.5 ml is intended for multiple use. 
Zdravilo Omnitrope 10 mg/1,5 ml je namenjeno za večkratno uporabo.
Rare side effects (likely to occur in fewer than 1 in 1,000 patients) include: 
Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 bolnikov) vključujejo:
Very common side effects (likely to occur in more than 1 in 10 patients) include: 
Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov) vključujejo:
- With one hand, pitch a fold of loose skin. 
- Z eno roko stisnite kožo v gubo.
0.035 mg/kg body weight per day or 1.0 mg/m2 body surface area per day. 
0,035 mg/kg telesne mase na dan ali 1,0 mg/m2 telesne površine na dan.